“Beginning 31 March, the US Food and Drug Administration’s (FDA) Office of the Commissioner will reorganize and make several changes to various offices within FDA, including the Office of New Drugs (OND).”
“With an eye toward efficiency and better connecting the Office of the Commissioner with center directors and other office leadership, outgoing FDA Commissioner Scott Gottlieb said in an email to staff on Thursday that the reorganization plan “elevates the role of the Centers in support of FDA’s science-driven culture, consolidates work in the Office of Operations to more effectively support the Agency’s mission and strengthens our staffing and recruiting functions.”
“Two major changes include the creation of the Office of Product Evaluation and Quality within the Center for Devices and Radiological Health (more details can be found here), and the creation of…” Read the full article here.
Source: Reorganization of FDA’s Office of the Commissioner to Begin Soon – By Zachary Brennan, March 21, 2019. RAPS.
